Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type()

The COVID-19 pandemic in the United States created a unique situation where multiple molecular SARS-CoV-2 diagnostic assays rapidly received Emergency Use Authorization by the FDA and were validated by laboratories and utilized clinically, all within a period of a few weeks. We compared the performa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lephart, Paul R., Bachman, Michael A., LeBar, William, McClellan, Scott, Barron, Karen, Schroeder, Lee, Newton, Duane W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Virology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470790/
https://www.ncbi.nlm.nih.gov/pubmed/32980807
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470790/
https://www.ncbi.nlm.nih.gov/pubmed/32980807
http://dx.doi.org/10.1016/j.diagmicrobio.2020.115200

Ejemplares similares